Physician profile
Temidayo A Adelekun
NPI 1962497537
$8,393.92
in general payments reported to CMS, 2019-2025
47 companies · $753 in 2025
The $753 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,722 · 2020: $708 · 2021: $1,835 · 2022: $1,402 · 2023: $1,102 · 2024: $872 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,632 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,632.36 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,614.27 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $765.46 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $642.89 | 2019-2022 | |
| Glaxosmithkline, LLC. | $600.25 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $446.06 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $398.42 | 2019-2023 | |
| Amgen INC. | $326.48 | 2019-2025 | Krystexxa, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $310.91 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $264.75 | 2019-2023 | Relistor |
| Biohaven Pharmaceuticals, INC. | $257.94 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $228.80 | 2021-2025 | |
| Gilead Sciences, INC. | $216.03 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $169.52 | 2022 | |
| Lilly USA, LLC | $163.46 | 2021-2025 | Jardiance, Mounjaro |
| Preventric Diagnostics, INC. | $156.70 | 2021 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Temidayo Adelekun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.